TheraRadar
← Back
Data updated: Jun 28, 2026

SEAGEN

Biotech
OncologyGastroenterologyImmunology Execution: Needs Improvement

SEAGEN is a biotechnology company focused on Oncology, Gastroenterology, Immunology. Key products include TUKYSA.

2020
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

FDA Novel Drug Designations

(2020-2021)
2 Novel 1 First-in-Class 1 Orphan 1 Breakthrough 1 Accelerated 2 Priority Review 1 Fast Track
See 2 novel approvals →
2021 TIVDAK (TISOTUMAB VEDOTIN-TFTV) First-in-Class · Priority Review · Accelerated
2020 TUKYSA (TUCATINIB) Orphan · Breakthrough · Priority Review · Fast Track

SEAGEN's Key Drugs

SEAGEN's core commercial portfolio centers on TUKYSA, TIVDAK, spanning Oncology and Gastroenterology — its most strategically important drugs approved in the last 15 years.

TUKYSA
Oncology

Breast Cancer

ERBB2 Approved 2020
TIVDAK
Oncology

Cervical Cancer

Tissue Factor Approved 2021

SEAGEN's Recent FDA Approvals

New NDA/BLA approvals for SEAGEN over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

SEAGEN's Therapeutic Areas

SEAGEN's approved drugs and pipeline span 3 therapeutic areas, led by Oncology and Gastroenterology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 89%
2 drugs Phase 3: 9 Phase 2: 28 Phase 1: 46
Gastroenterology 9%
0 drugs Phase 2: 4 Phase 1: 7
Immunology 2%
0 drugs Phase 2: 1 Phase 1: 1

SEAGEN's Top Competitors

SEAGEN's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Johnson & Johnson big-pharma
Oncology, Immunology, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Gastroenterology
Takeda big-pharma
Immunology, Gastroenterology, Oncology
Pfizer big-pharma
Oncology, Immunology
PF PRISM CV big-pharma
Oncology, Immunology, Gastroenterology

SEAGEN Pipeline Snapshot

SEAGEN has 96 active clinical programs from ClinicalTrials.gov — 9 Phase 3, 33 Phase 2 and 54 Phase 1.

9
Phase 3
33
Phase 2
54
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • TUKYSA leads revenue
  • • 2 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking
View full pipeline →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 1/7 completed
  • • Speed: 56 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges